Relmada Therapeutics Inc (RLMD)
3.83
-0.02
(-0.52%)
USD |
NASDAQ |
May 07, 13:20
Relmada Therapeutics Enterprise Value: 19.85M for May 6, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 06, 2024 | 19.85M |
| May 03, 2024 | 14.72M |
| May 02, 2024 | 15.92M |
| May 01, 2024 | 15.02M |
| April 30, 2024 | 13.51M |
| April 29, 2024 | 10.19M |
| April 26, 2024 | 19.24M |
| April 25, 2024 | 15.32M |
| April 24, 2024 | 20.15M |
| April 23, 2024 | 21.66M |
| April 22, 2024 | 20.45M |
| April 19, 2024 | 24.37M |
| April 18, 2024 | 33.43M |
| April 17, 2024 | 44.89M |
| April 16, 2024 | 41.27M |
| April 15, 2024 | 37.95M |
| April 12, 2024 | 43.99M |
| April 11, 2024 | 44.29M |
| April 10, 2024 | 39.76M |
| April 09, 2024 | 48.51M |
| April 08, 2024 | 50.32M |
| April 05, 2024 | 42.18M |
| April 04, 2024 | 45.19M |
| April 03, 2024 | 45.80M |
| April 02, 2024 | 52.74M |
| Date | Value |
|---|---|
| April 01, 2024 | 50.93M |
| March 28, 2024 | 43.99M |
| March 27, 2024 | 42.18M |
| March 26, 2024 | 45.19M |
| March 25, 2024 | 51.53M |
| March 22, 2024 | 50.32M |
| March 21, 2024 | 44.29M |
| March 20, 2024 | 37.50M |
| March 19, 2024 | 65.71M |
| March 18, 2024 | 70.24M |
| March 15, 2024 | 67.22M |
| March 14, 2024 | 55.08M |
| March 13, 2024 | 73.44M |
| March 12, 2024 | 70.12M |
| March 11, 2024 | 77.35M |
| March 08, 2024 | 94.81M |
| March 07, 2024 | 95.41M |
| March 06, 2024 | 96.31M |
| March 05, 2024 | 93.90M |
| March 04, 2024 | 94.81M |
| March 01, 2024 | 108.35M |
| February 29, 2024 | 88.03M |
| February 28, 2024 | 88.49M |
| February 27, 2024 | 82.16M |
| February 26, 2024 | 81.56M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-118.84M
Minimum
Dec 08 2022
876.17M
Maximum
Sep 30 2022
276.72M
Average
332.68M
Median
Jun 08 2022
Enterprise Value Benchmarks
| Cyclacel Pharmaceuticals Inc | -0.6359M |
| Lifecore Biomedical Inc | -- |
| Harrow Inc | 471.36M |
| Corvus Pharmaceuticals Inc | 67.01M |
| Aquestive Therapeutics Inc | 260.21M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -25.17M |
| Total Expenses (Quarterly) | 26.83M |
| EPS Diluted (Quarterly) | -0.83 |
| Earnings Yield | -85.38% |
| Normalized Earnings Yield | -0.9042 |